To determine whether CD19/NKG2DL tandem CAR T-cells can effectively target primary B-ALL tumor cells, we incubated T-cells expressing the tandem with the CD8 short hinge, alongside mock and single CAR T-cells, with CD19+ bone marrow specimen from two B-ALL patients (Immunophenotyping available in Table 1). This evidence concerns the gene CD8A and neoplasm.